Patents by Inventor Xiaojun Liu

Xiaojun Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12344843
    Abstract: The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR ? chain, TCR ? chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS and further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: July 1, 2025
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Jiangtao Ren, Xiaojun Liu, Carl H. June
  • Patent number: 12337359
    Abstract: A method for detecting wafer cleaning anomalies includes: capturing a wafer cleaning video in real time through each of a plurality of cameras of cleaning machines, each camera corresponds to a respective cleaning chamber of one of the cleaning machines, and each cleaning chamber contains a nozzle; performing image processing on each frame of image contained in the wafer cleaning video to obtain characteristics of contact between a cleaning water column dispensed from the nozzle and a wafer in the image, and determining through the characteristics of contact whether the nozzle has an anomaly; and when a target nozzle having the anomaly is detected, determining anomaly positioning information of the target nozzle, and performing anomaly early-warning by using the anomaly positioning information.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: June 24, 2025
    Assignee: CHANGXIN MEMORY TECHNOLOGIES, INC.
    Inventors: Guobiao Jiang, Xiaojun Liu
  • Patent number: 12321157
    Abstract: A state monitoring method, a state monitoring apparatus and a state monitoring system for a developing device are provided. After image information is obtained through the acquired video information of the developing device, it is determined by an analysis unit whether the image information includes nozzle anomaly information, and alarm information is issued after the nozzle anomaly information is determined. Moreover, similarity between the image information that does not include the nozzle anomaly information and second preset nozzle anomaly information is compared, and the nozzle information is stored in the analysis unit in a case that the similarity between the image information and the second preset nozzle anomaly information is greater than a first threshold.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: June 3, 2025
    Assignee: CHANGXIN MEMORY TECHNOLOGIES, INC.
    Inventor: Xiaojun Liu
  • Publication number: 20250163132
    Abstract: The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.
    Type: Application
    Filed: December 23, 2024
    Publication date: May 22, 2025
    Inventors: Yangbing Zhao, Carl H. June, Xiaojun Liu
  • Publication number: 20250154223
    Abstract: The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.
    Type: Application
    Filed: January 17, 2025
    Publication date: May 15, 2025
    Inventors: Yangbing Zhao, Xiaojun Liu, Wei Pan
  • Publication number: 20250115966
    Abstract: A SNP molecular marker combination for identifying an AA broiler includes 25 SNP molecular markers, SNP sites of the SNP molecular markers 1 to 25 are located at a 51st position of each of nucleotide sequences shown in SEQ ID NO: 1 to 25. The SNP molecular marker combination for identifying the AA broiler in the disclosure has apparent species specificity of the AA broiler, is a unique mutation and importance determining site for the AA broiler, and can quickly identify authenticity of the AA broiler with less genotype information, providing new technical references for the identification, conservation, and genetic breeding of chicken breeds in the future.
    Type: Application
    Filed: July 3, 2024
    Publication date: April 10, 2025
    Inventors: Xiangtao Kang, Zhuanjian Li, Yanxing Wang, Tong Li, Yadong Tian, Ruili Han, Hong Li, Xiaojun Liu, Weihua Tian, Ruirui Jiang, Guoxi Li, Wenting Li, Fengbin Yan, Yanbin Wang
  • Patent number: 12247087
    Abstract: The present application provides a biological active peptide from seawater pearl, the sequence of which is Ile-Pro-Ser-Thr-Thr-Pro-Phe-Pro-Ser-Thr-Thr-Val-Ala-Thr-Thr-Thr-Met, and the name of which is SCOL polypeptide. The biological active peptide can improve an ACE2 enzyme activity to 3.76 times, and can be applied in preparation of a drug improving an ACE2 activity, treating hypertension, anti-heart failure, anti-tissue fibrosis, anti-inflammation, and type 2 diabetes mellitus and the complication thereof, and relieving neuropathic pain. The biological active peptide can be specifically bound to the ACE2, effectively inhibits the 65% binding between novel coronavirus S protein and the ACE2, can be applied in preparation of an anti-coronavirus infection drug as an inhibitor, and specifically applied in preparation of anti-novel coronavirus drug.
    Type: Grant
    Filed: January 18, 2024
    Date of Patent: March 11, 2025
    Assignees: ZHEJIANG QINGRONG BIOTECHNOLOGY DEVELOPMENT CO., LTD, YANGTZE DELTA REGION INSTITUTE OF TSINGHUA UNIVERSITY, ZHEJIANG
    Inventors: Xiaojun Liu, Rongqing Zhang, Jing Zhang, Zehui Yin, Liping Yao, Zhen Zhang
  • Patent number: 12227555
    Abstract: The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: February 18, 2025
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Xiaojun Liu, Wei Pan
  • Patent number: 12215137
    Abstract: The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: February 4, 2025
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Carl H. June, Xiaojun Liu
  • Patent number: 12162922
    Abstract: The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: December 10, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Devon J. Shedlock, Carl H. June, Xiaojun Liu
  • Publication number: 20240376150
    Abstract: The present application provides a biological active peptide from seawater pearl, the sequence of which is Ile-Pro-Ser-Thr-Thr-Pro-Phe-Pro-Ser-Thr-Thr-Val-Ala-Thr-Thr-Thr-Met, and the name of which is SCOL polypeptide. The biological active peptide can improve an ACE2 enzyme activity to 3.76 times, and can be applied in preparation of a drug improving an ACE2 activity, treating hypertension, anti-heart failure, anti-tissue fibrosis, anti-inflammation, and type 2 diabetes mellitus and the complication thereof, and relieving neuropathic pain. The biological active peptide can be specifically bound to the ACE2, effectively inhibits the 65% binding between novel coronavirus S protein and the ACE2, can be applied in preparation of an anti-coronavirus infection drug as an inhibitor, and specifically applied in preparation of anti-novel coronavirus drug.
    Type: Application
    Filed: January 18, 2024
    Publication date: November 14, 2024
    Inventors: Xiaojun LIU, Rongqing Zhang, Jing Zhang, Zehui Yin, Liping Yao, Zhen Zhang
  • Publication number: 20240279665
    Abstract: The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR ? chain, TCR ? chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS and further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.
    Type: Application
    Filed: September 15, 2023
    Publication date: August 22, 2024
    Inventors: Yangbing Zhao, Jiangtao Ren, Xiaojun Liu, Carl H. June
  • Patent number: 11992503
    Abstract: The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: May 28, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Szu Hua Sharon Lin, Xiaojun Liu, Anne Chew
  • Patent number: 11993659
    Abstract: Disclosed herein are anti-BCMA antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-BCMA antibodies and antigen-binding fragments (“BCMA CARs”) and genetically modified immune effector cells having such BCMA CARs. Polynucleotides encoding the anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. Compositions comprising anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. The present disclosure also relates to use of the anti-BCMA antibodies and antigen-binding fragments and genetically modified immune effector cells having such BCMA CARs in cancer treatment.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: May 28, 2024
    Assignee: UTC THERAPEUTICS (SHANGHAI) CO., LTD.
    Inventors: Yangbing Zhao, Wei Pan, Xiaojun Liu
  • Publication number: 20240159934
    Abstract: A system and a method are provided. The system includes an airborne detection system and a ground assistance system. The airborne detection system includes an unmanned aerial vehicle, a receiving device, a transmitting device, and a connecting device. The transmitting device includes a transmitting sub-device, a transmitting coil, and a bucking coil. The receiving device includes a receiving sub-device and a three-component magnetic sensor. The connecting device includes a signal and rope composite cable and is used to connect the UAV, the transmitting device, and the receiving device. The three-component magnetic sensor is used to acquire three-component electromagnetic data. The bucking coil is disposed on an inner side of the transmitting coil, and coil winding direction of the transmitting coil and the bucking coil causes current directions flowing through the transmitting coil and the bucking coil to be opposite to each other, to reduce an electromagnetic interference.
    Type: Application
    Filed: September 25, 2023
    Publication date: May 16, 2024
    Applicant: Aerospace Information Research Institute, Chinese Academy of Sciences
    Inventors: Lihua LIU, Ling HUANG, Jiankai LI, Zhen KE, Shichu YAN, Xiaojun LIU, Guangyou FANG
  • Patent number: 11897966
    Abstract: Disclosed herein are anti-mesothelin antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-mesothelin antibodies and antigen-binding fragments (“mesothelin CARs”) and genetically modified immune effector cells having such mesothelin CARs. Polynucleotides encoding the anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. Compositions comprising anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. The present disclosure also relates to uses of the anti-mesothelin antibodies and antigen-binding fragments and genetically modified immune effector cells having such mesothelin CARs in cancer treatment.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: February 13, 2024
    Assignee: UTC THERAPEUTICS (SHANGHAI) CO., LTD.
    Inventors: Yangbing Zhao, Gengzhen Zhu, Xiaojun Liu
  • Publication number: 20240041928
    Abstract: The present disclosure provides modified immune cell (e.g., modified T cell) comprising an exogenous T cell receptor (TCR) having specificity for NY-ESO-1. The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising an exogenous TCR and a switch receptor. Gene edited modified cells are also provided, such that the expression of one or more of an endogenous T-cell receptor gene (e.g., TRAC, TRBC) or an endogenous immune checkpoint gene (e.g. PD-1 or TIM-3) is downregulated.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 8, 2024
    Inventors: Yangbing Zhao, Xiaojun Liu
  • Patent number: 11878229
    Abstract: A stroke decision device 30 includes an acquisition section 31 configured to acquire state information including a position, a velocity, and a rotational velocity of an incoming ball, and a stroke decision section 32 configured to decide a stroke condition including a position, a velocity, and an orientation of a striking implement at a time point when hitting back the ball toward a target arrival position, based on the state information for the ball and the target arrival position when hitting back the ball with the striking implement.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: January 23, 2024
    Assignee: OMRON CORPORATION
    Inventors: Xiaojun Liu, Kyohei Asai, Masamune Nakayama, Satoshi Yase
  • Publication number: 20240018603
    Abstract: The present disclosure relates to a molecular marker of the IGF2BP1 gene related to a chicken body size trait and the use thereof, and a genetic improvement method. In the present disclosure, it is found by means of gene association analysis that a deletion mutation in a promoter region of the IGF2BP1 gene of chicken is significantly associated with the chicken body size trait.
    Type: Application
    Filed: October 3, 2023
    Publication date: January 18, 2024
    Applicant: HENAN AGRICULTURAL UNIVERSITY
    Inventors: Xiangtao KANG, Wenting LI, Kejun WANG, Yadong TIAN, Guirong SUN, Ruili HAN, Ruirui JIANG, Donghua LI, Guoxi LI, Zhuanjian LI, Xiaojun LIU, Hong LI
  • Publication number: 20240018271
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.
    Type: Application
    Filed: September 29, 2023
    Publication date: January 18, 2024
    Inventors: Carl H. June, Yangbing Zhao, Xiaojun Liu